RB1 and cancer: CDK4/6–phosphorylated RB1 has been shown to promote anticancer immunity by inhibiting nuclear factor-κB activation and programmed death-ligand 1 expression (Jin et al., 2019), further indicating the immunological relevance of palbociclib during cancer treatment.